Epstein Secrets

rated EAI: 34,500 CLerent yield: 4.94% Original cost basis 393,704.74 Nov 14, 11 90.000.000 100.673 90,606.32 101.220 91,098 00 491 68 LT MICHIGAN MUN 8D AUTH RV RUN RATE 05.000% MATURES 1001126 CALLABLE 11/30/16 9 100.00 ACCRUED INTEREST 320.83 CUSJP 59455T485 Moody. Aaa SSP: AAA EAL 3

ce value a mattsity (4) Purchase pnced) Aduded cost basas Price on Aug 31 (5) Sue on Aug 31 (51 Unrealized gen or loss (S) Hddng period MICHIGAN MUN BO RUTH RV PREF BEM PRE.REFUNOECI RATE 05.000% MATURES 1001126 PREFERiNDED 1001(16 0 100.00 ACCRUED INTEREST 4937.49 CUSrP 5945573R1 Mood

ty repented vats no question, or when a value would be highy speadatime due to tie nature c4 the murky. - When neither an Muer, general partner or Venter estimated value nor a thed-paly estimated vats is market the maturate security Mite dderent from its ;ached price. - • Daributicns to date' may i

their own music - all by ear. The first location debuted in 2010 in Vero Beach, Florida, followed in 2011 with Fayetteville, Arkansas, and Saline, Michigan in 2012. The world-class faculty has included Darol Anger, Hanneke Cassel, Joe Craven, Rushad Eggleston, Brittany Haas, Natalie Haas, Jeremy Kitte

icated to human, microbial, plant, synthetic and environmental genomic research, and the exploration of social and ethical issues in genomics. Dr. Venter is also Founder and CEO of Synthetic Genomics Inc (Sal), a privately held company dedicated to commercializing genomic-driven solutions to address

ge their own music - all by ear. The first location debuted in 2010 in Vero Beach, Florida, followed in 2011 with Fayetteville, Arkansas, and Saline, Michigan in 2012. The world-class faculty has included Darol Anger, Hanneke Cassel, Joe Craven, Rushad Eggleston, Brittany Haas, Natalie Haas, Jeremy Kittel,

edicated to human, microbial, plant, synthetic and environmental genomic research, and the exploration of social and ethical issues in genomics. Dr. Venter is also Founder and CEO of Synthetic Genomics Inc (SGI), a privately held company dedicated to commercializing genomic-driven solutions to address gl